5 results on '"Elsayed, Yusri"'
Search Results
2. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
- Author
-
Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang TY, Hilder BW, Jiao Q, Hanna B, Adams HC 3rd, Sun YN, Sharma A, Smit J, Infante JR, Goldberg JD, and Elsayed Y
- Subjects
- Administration, Intravenous, B-Cell Maturation Antigen, Humans, Antineoplastic Agents therapeutic use, Multiple Myeloma drug therapy
- Abstract
Background: Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies., Objective: A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evaluating teclistamab in patients with relapsed/refractory multiple myeloma., Patients and Methods: To estimate the efficacious therapeutic dosing range of teclistamab, pharmacokinetic (PK) data following the first cycle doses in the low-dose cohorts in the Phase I study were modeled using a 2-compartment model and simulated to predict the doses that would have average and trough serum teclistamab concentrations in the expected therapeutic range (between EC
50 and EC90 values from an ex vivo cytotoxicity assay)., Results: The doses predicted to have average serum concentrations between the EC50 and EC90 range were validated. In addition, simulations showed that weekly intravenous and subcutaneous doses of 0.70 mg/kg and 0.72 mg/kg, respectively, resulted in mean trough levels comparable to the maximum EC90 . The most active doses in the Phase I study were weekly intravenous doses of 0.27 and 0.72 mg/kg and weekly subcutaneous doses of 0.72 and 1.5 mg/kg, with the weekly 1.5 mg/kg subcutaneous doses selected as the recommended Phase II dose (RP2D). With active doses, exposure was maintained above the mean EC90 . All patients who responded to the RP2D of teclistamab had exposure above the maximum EC90 in both serum and bone marrow on cycle 3, Day 1 of treatment., Conclusions: Our findings show that PK simulations of early clinical data together with ex vivo cytotoxicity estimates can inform the identification of a bispecific antibody's therapeutic range., Clinical Trial Registration: NCT03145181, date of registration: May 9, 2017., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
3. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
- Author
-
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, and Krishnan A
- Subjects
- Administration, Intravenous, Aged, Antibodies, Monoclonal, Humanized administration & dosage, B-Cell Maturation Antigen immunology, Dose-Response Relationship, Drug, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, T-Lymphocytes drug effects, T-Lymphocytes immunology, Treatment Outcome, Antibodies, Bispecific pharmacology, Antineoplastic Agents, Immunological therapeutic use, B-Cell Maturation Antigen therapeutic use, Multiple Myeloma drug therapy
- Abstract
Background: There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the safety, tolerability, and preliminary efficacy of teclistamab in patients with relapsed or refractory multiple myeloma., Methods: This open-label, single-arm, phase 1 study enrolled patients with multiple myeloma who were relapsed, refractory, or intolerant to established therapies. Teclistamab was administered intravenously (range 0·3-19·2 μg/kg [once every 2 weeks] or 19·2-720 μg/kg [once per week]) or subcutaneously (range 80-3000 μg/kg [once per week]) in different cohorts, with step-up dosing for 38·4 μg/kg or higher doses. The primary objectives were to identify the recommended phase 2 dose (part one) and characterise teclistamab safety and tolerability at the recommended phase 2 dose (part two). Safety was assessed in all patients treated with at least one dose of teclistamab. Efficacy was analysed in response-evaluable patients (ie, patients who received at least one dose of teclistamab and had at least one post-baseline response evaluation). This ongoing trial is registered with ClinicalTrials.gov, NCT03145181., Findings: Between June 8, 2017, and March 29, 2021, 219 patients were screened for study inclusion, and 157 patients (median six previous therapy lines) were enrolled and received at least one dose of teclistamab (intravenous n=84; subcutaneous n=73). 40 patients were administered the recommended phase 2 dose, identified as once per week subcutaneous administration of teclistamab at 1500 μg/kg, after 60 μg/kg and 300 μg/kg step-up doses (median follow-up 6·1 months, IQR 3·6-8·2). There were no dose-limiting toxicities at the recommended phase 2 dose in part one. In the 40 patients treated at the recommended phase 2 dose, the most common treatment-emergent adverse events were cytokine release syndrome in 28 (70%; all grade 1 or 2 events) and neutropenia in 26 (65%) patients (grade 3 or 4 in 16 [40%]). The overall response rate in response-evaluable patients treated at the recommended phase 2 dose (n=40) was 65% (95% CI 48-79); 58% achieved a very good partial response or better. At the recommended phase 2 dose, the median duration of response was not reached. 22 (85%) of 26 responders were alive and continuing treatment after 7·1 months' median follow-up (IQR 5·1-9·1). At the recommended phase 2 dose, teclistamab exposure was maintained above target exposure levels, and consistent T-cell activation was reported., Interpretation: Teclistamab is a novel treatment approach for relapsed or refractory multiple myeloma. At the recommended phase 2 dose, teclistamab showed promising efficacy, with durable responses that deepened over time, and was well tolerated, supporting further clinical development., Funding: Janssen Research & Development., Competing Interests: Declaration of interests SZU received grant support from Bristol Myers Squibb and Pharmacyclics; grant support and consulting fees from Amgen, Celgene, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDx, Merck, and GlaxoSmithKline; and consulting fees from AbbVie, Karyopharm, and Mundipharma. ALG received grant support from Novartis and CRISPR Therapeutics; grant support and consulting fees from Janssen and Tmunity Therapeutics; consulting fees from GlaxoSmithKline and Surface Oncology; and holds a pending patent (15/757,123) with royalties paid, and pending patents (16/768,260 and 16/746,459) licensed to Novartis. NWCJvdD received grant support and advisory board fees from Bristol Myers Squibb/Celgene, Janssen, Novartis, and Amgen; advisory board fees from Takeda, Servier, Bayer, Adaptive Biotechnologies, Roche, GlaxoSmithKline, and Sanofi; and grant support from Cellectis. JFS-M received consulting and advisory board fees from Amgen, Celgene, Takeda, Bristol Myers Squibb, Merck, Sharp & Dohme, Novartis, Sanofi, Janssen, Roche, AbbVie, GlaxoSmithKline, Karyopharm Therapeutics, and Secura Bio. AO received consulting fees from Amgen, Celgene, Sanofi, Janssen, and GlaxoSmithKline. LR received consulting fees from Amgen, Celgene, Sanofi, Janssen, and Takeda. AC received grant support and consulting fees from Amgen, Janssen, Celgene, Novartis Pharmaceuticals, Seattle Genetics, Millennium/Takeda; consulting fees from Bristol Myers Squibb, Karyopharm, Sanofi, Oncopeptides, Antengene, GlaxoSmithKline, Secura Bio, Shattuck Labs; and grant support from Pharmacyclics. MB received payment for speaker bureaus from Amgen, Bristol Myers Squibb, and Takeda; served as a consultant for Sanofi Genzyme; and received grant support from Janssen, MedImmune, Takeda, Prothena, Bristol Myers Squibb/Celgene, Cerecor, and Celularity. LK received consulting fees from Janssen-Cilag, Celgene, Amgen, Takeda, and GlaxoSmithKline. LP, RV, SG, TS, YE, JI, JDG, and AB are employed by Janssen. M-VM received consulting fees from Janssen-Cilag, GlaxoSmithKline, Celgene, Amgen, Regeneron, Pfizer, AbbVie, Takeda, Roche/Genentech, and Adaptive Biotechnologies. AK received consulting fees from Janssen Oncology, GlaxoSmithKline, Celgene, Adaptive Biotechnologies, Regeneron, Pfizer, Bristol-Myers Squib, Takeda, and Sutro Biopharma. HN and LB declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
4. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
- Author
-
Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonça M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, and Gaudet F
- Subjects
- Animals, B-Cell Maturation Antigen, Humans, Lymphocyte Activation, Mice, T-Lymphocytes, Antibodies, Bispecific pharmacology, Multiple Myeloma drug therapy
- Abstract
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells. BCMA is highly expressed on plasmablasts and plasma cells from multiple myeloma (MM) patient samples. We developed a BCMAxCD3 bispecific antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells. Teclistamab induced cytotoxicity of BCMA+ MM cell lines in vitro (H929 cells, 50% effective concentration [EC50] = 0.15 nM; MM.1R cells, EC50 = 0.06 nM; RPMI 8226 cells, EC50 = 0.45 nM) with concomitant T-cell activation (H929 cells, EC50 = 0.21 nM; MM.1R cells, EC50 = 0.1 nM; RPMI 8226 cells, EC50 = 0.28 nM) and cytokine release. This activity was further increased in the presence of a γ-secretase inhibitor (LY-411575). Teclistamab also depleted BCMA+ cells in bone marrow samples from MM patients in an ex vivo assay with an average EC50 value of 1.7 nM. Under more physiological conditions using healthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells. Antitumor activity of teclistamab was also observed in 2 BCMA+ MM murine xenograft models inoculated with human T cells (tumor inhibition with H929 model and tumor regression with the RPMI 8226 model) compared with vehicle and antibody controls. The specific and potent activity of teclistamab against BCMA-expressing cells from MM cell lines, patient samples, and MM xenograft models warrant further evaluation of this bispecific antibody for the treatment of MM. Phase 1 clinical trials (monotherapy, #NCT03145181; combination therapy, #NCT04108195) are ongoing for patients with relapsed/refractory MM., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
5. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
- Author
-
Pillarisetti K, Edavettal S, Mendonça M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D, Luistro L, Joseph J, Chu G, Packman K, Shetty S, Elsayed Y, Attar R, and Gaudet F
- Subjects
- Animals, Antibodies, Bispecific immunology, Antineoplastic Agents, Immunological immunology, Cell Line, Tumor, Cytotoxicity, Immunologic drug effects, Female, Humans, Immunotherapy, Mice, Inbred BALB C, Multiple Myeloma immunology, T-Lymphocytes immunology, Antibodies, Bispecific therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Multiple Myeloma therapy, Receptors, G-Protein-Coupled immunology, T-Lymphocytes drug effects
- Abstract
T-cell-mediated approaches have shown promise in myeloma treatment. However, there are currently a limited number of specific myeloma antigens that can be targeted, and multiple myeloma (MM) remains an incurable disease. G-protein-coupled receptor class 5 member D (GPRC5D) is expressed in MM and smoldering MM patient plasma cells. Here, we demonstrate that GPRC5D protein is present on the surface of MM cells and describe JNJ-64407564, a GPRC5DxCD3 bispecific antibody that recruits CD3+ T cells to GPRC5D+ MM cells and induces killing of GPRC5D+ cells. In vitro, JNJ-64407564 induced specific cytotoxicity of GPRC5D+ cells with concomitant T-cell activation and also killed plasma cells in MM patient samples ex vivo. JNJ-64407564 can recruit T cells and induce tumor regression in GPRC5D+ MM murine models, which coincide with T-cell infiltration at the tumor site. This antibody is also able to induce cytotoxicity of patient primary MM cells from bone marrow, which is the natural site of this disease. GPRC5D is a promising surface antigen for MM immunotherapy, and JNJ-64407564 is currently being evaluated in a phase 1 clinical trial in patients with relapsed or refractory MM (NCT03399799)., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.